Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow

• Dhruv Bansal,
• Kiran Vij,
• Gue Su Chang,
• Christopher A. Miller,
• John F. DiPersio,
• Ravi Vij,
• Sharon E. Heath,
• Peter Westervelt,
• John S. Welch,
• Todd A. Fehniger

Affiliations

Dhruv Bansal

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Kiran Vij

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Gue Su Chang

McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO, USA

Christopher A. Miller

McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO, USA

John F. DiPersio

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Ravi Vij

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Sharon E. Heath

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Peter Westervelt

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

John S. Welch

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

Todd A. Fehniger

Department of Medicine, Division of Oncology, BMT and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA